DAIC

APRIL 30, 2024

Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure , a leading cause of hospitalization and death. hospitals from emergency rooms.

Heart Failure 105

Heart Failure Hospital Research COVID-19 105

Open Heart

JULY 20, 2022

Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. Outcome measures were (1) all-cause hospitalisations, (2) outpatient clinic attendances and (3) cost. Results 334 patients (mean age 72.5±11 ±4 months.

Heart Failure 52

Heart Failure Kidney Disease Outpatient Nursing 52

Stroke Journal

FEBRUARY 1, 2024

The ADA recommends in patients with ASCVD, when prevention of further vascular events is the priority, a GLP1RA should be added; and when concern for heart failure or chronic kidney disease is the priority, a SGLT2i should be added.Objective:Among a cohort of patients with diabetes presenting with AIS, we analyzed rates of GLP1RA and SGLT2i use during (..)

Diabetes 40

Diabetes Stroke Strokes Kidney Disease 40

Open Heart

SEPTEMBER 27, 2023

Background Heart failure (HF), type 2 diabetes (T2D) and chronic kidney disease (CKD) commonly coexist. In multivariable analyses, we identified risk factors for developing the third condition and mortality, such as age, sex, medical history and the order of disease diagnosis.

Risk Factors 52

Risk Factors Kidney Disease Heart Failure Diabetes 52

DAIC

APRIL 6, 2024

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin.

Heart attacks 98

Heart attacks Heart Attack Heart Failure Outpatient 98

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

Heart attacks 81

Heart attacks Heart Attack Heart Failure Outcomes 81

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

In multivariate regression analysis, the factors independently associated with a greater risk of readmission within 90 days were hypercoagulation (1.359 [95%CI, 1.1274‐1.45]), opiod abuse and dependence (1.353 [95%CI, 1.238‐1.478]), chronic kidney disease (1.347 [95%CI, 1.316‐1.379]), liver disease (1.318 [95% CI, 1.26‐1.378]),

Risk Factors 40

Risk Factors Stroke Strokes Medicare 40